Found 1576 clinical trials
-
Multi-country trial
-
Phase 1 trial
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Hematology
-
Currently Recruiting
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Refractory Follicular Lymphoma (CITADEL-102)
- 560 views
- 23 Nov, 2020
- 12 locations
-
Accepting Seniors
-
Accepting adults
-
For all genders
-
Hematology
-
Currently Recruiting
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)
(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these
- 88 views
- 15 Apr, 2019
- 1 location
-
Accepting Seniors
-
Accepting adults
-
For all genders
-
Oncology
-
Currently Recruiting
REAL Registry PI3K-inhibitors
People with lymphoma are asked to participate in a research study being conducted by Queens Hospital Center.
- 0 views
- 07 Jul, 2020
- 1 location
-
Multi-country trial
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Hematology
-
Currently Recruiting
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma
- 304 views
- 23 Nov, 2020
- 6 locations
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US
(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system
- 1875 views
- 26 Mar, 2021
- 15 locations
-
Accepting Seniors
-
Accepting adults
-
For all genders
-
Hematology
-
Currently Recruiting
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia (CLL) is a cancer of white blood cells. It is also called small lymphocytic lymphoma (SLL). It causes tiredness, night sweats
- 47 views
- 23 Nov, 2020
- 1 location
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish
(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system
- 268 views
- 26 Mar, 2021
- 16 locations
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Currently Recruiting
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma
- 590 views
- 23 Nov, 2020
- 5 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
For all genders
-
Hematology
-
Currently Recruiting
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Background: Chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) are tumors of abnormal B cells that often affect elderly patients. Studies have
- 69 views
- 15 Apr, 2019
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Currently Recruiting
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK
- 98 views
- 23 Nov, 2020
- 1 location